Demand for immunity products to be sustained long-term say SIRIO
Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19
11 May, 2020: SIRIO Europe (Ayanda) – the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO) – says considerable worldwide demand for immunity products has accelerated in recent months due coronavirus, but it is also likely to deliver a permanent ‘new norm’ of higher growth.
“Already in Europe, we have seen a significant spike in the demand for immunity products across the main economies. In fact, recent weekly data from Euromonitor shows an increased purchasing of Vitamin C and Multivitamins by consumers, with unusual levels of stockouts present throughout Europe. While production and supply chains have been pretty robust during lockdowns, we have still seen large stock shortages. This is particularly surprising, as we are now approaching summer, which is not traditionally a peak period for these products. Anticipating a surge, we secured a very large inventory of ingredients to ensure continuity of supply for all customers” commented Dr. Dominique Baum, Managing Director at SIRIO Europe (Ayanda).
Additionally, confinement regulations leaving consumers with reduced exposure to sunlight has increased sales of nutraceuticals containing vitamin D or other ingredients that compensate the lack of natural daylight. Consumers are also purchasing products that strengthen their respiratory and cardiovascular systems, with Omega-3 fatty acids and antioxidants – that may protect against oxidative stress – proving popular. The long-term cumulative effect the company suggests will be continued growth in health boosting and immune boosting supplements, adding a further driver to an already expanding nutraceuticals class.
For example, the consumer movement towards more healthier lifestyles and immunity-boosting products in the last couple of years has seen a significant growth in probiotics, which help stabilize the microbiome – an essential regulator of equilibrium in immunity. Notably, last year, SIRIO Europe secured a European patent for softgel capsules able to contain an active probiotic bacteria, as well as at least one oil (e.g., Omega 3). The product now has six months of stability data and customer interest is increasing quickly.
“The lasting impact of the virus will see a further acceleration of an already popular product class and, in the next few years, we will likely see many new innovative immune formulations delivered via softgels and gummies. Consumers will be looking for new ways to potentially boost health and immunity with combination products, and we anticipate those products with multiple actives are likely to be increasingly popular. It’s difficult time for society, but it could lead to further improvements with an increased consumer focus on wellbeing” added Baum.
Founded in 1993, Sirio Pharma Co., Ltd (SIRIO) is the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgel, gummy, capsule, tablet, powder, oral liquid, probiotics and other dosage forms. The company has extensive capabilities with multiple manufacturing sites in China, as well as manufacturing facilities in Europe and marketing teams in the USA. SIRIO is devoted to offering one-stop solutions including product developing, manufacturing, packaging and logistics to its customers.
SIRIO is approved by TGA-GMP, NPA/UL GMP, BRC, UL's Management System 21 CFR Part 111, ISO 9001:2015 certification, and etc. Cooperating with many well-known nutraceutical companies, SIRIO is committed to providing products and service to customers all around the world.
De Facto Communications
Alex Heeley or Abdul Khalifeh
Contact: +44 203 735 8168
email@example.com / firstname.lastname@example.org